Spinocerebellar Ataxias - Pipeline Insight, 2020
This report can be delivered to the clients within 24-48 Hours
DelveInsight’s, “Spinocerebellar Ataxias – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Spinocerebellar Ataxias pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Spinocerebellar Ataxias: Overview
The Spinocerebellar ataxias (SCA) are a subset of hereditary cerebellar ataxias that are autosomal dominantly transmitted. They are progressive neurodegenerative diseases that share the clinical features of ataxia, which arise from the progressive degeneration of the cerebellum but can also affect other connected regions, including the brain stem. They are a highly heterogenous group of disorders with a complex genotype–phenotype spectrum; many SCAs are caused by CAG nucleotide repeat expansions that encode polyglutamine, and therefore, involve the toxic polyglutamine protein (polyQ).
The spinocerebellar ataxias (SCAs) are a large complex group of inherited neurodegenerative disorders characterized by progressive cerebellar ataxia, ocular motor abnormalities, and a range of other variable neurologic features, including retinopathy, optic atrophy, peripheral neuropathy, extrapyramidal symptoms, and cognitive dysfunction.
Symptoms
A phenotype-first approach remains pertinent in molecular diagnosis of rare genetic disorders. Clinicians should also consider genetic testing for primary episodic ataxias (EA). Advances in next-generation sequencing (NGS) have facilitated further insights into the molecular causes of SCA. Exome sequencing identifies less classical phenotype–genotype correlations and detects new mutations in known cerebellar genes.
Treatment
Advancements in the understanding of pathophysiologic mechanisms facilitate the potential to find new therapeutic targets. Riluzole, a drug licensed for the treatment of ALS, was reconsidered for the treatment of patients with ataxia owing to its ability to inhibit presynaptic glutamate release and activate calcium-activated potassium channels.The anticonvulsant valproic acid has been proposed as a pharmacological treatment in SCA3/MJD for its neuroprotective properties as a pan-histone deacetylase inhibitor. Lithium carbonate was evaluated in 62 ambulatory patients with SCA3/MJD for 48 weeks, but no difference was seen in mean scores of the neurological scale for ataxia. Varenicline is a partial agonist of the ?4?2 neuronal nicotinic acetylcholine receptor that is used to aid the cessation of smoking. Varenicline was anecdotally reported to have beneficial effects in patients with ataxia that were taking it as part of a smoking cessation programme. General supportive management options include physiotherapy, occupational therapy and speech therapy. Physiotherapy focused on improving gait, balance, coordination, posture and muscle strength is often recommended.
Spinocerebellar Ataxias Emerging Drugs Chapters
This segment of the Spinocerebellar Ataxias report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spinocerebellar Ataxias Emerging Drugs
Further product details are provided in the report……..
Spinocerebellar Ataxias: Therapeutic Assessment
This segment of the report provides insights about the different Spinocerebellar Ataxias drugs segregated based on following parameters that define the scope of the report, such as:
Spinocerebellar Ataxias: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinocerebellar Ataxias therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinocerebellar Ataxias drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Spinocerebellar Ataxias – Pipeline Insight, 2020,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Spinocerebellar Ataxias pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Spinocerebellar Ataxias: Overview
The Spinocerebellar ataxias (SCA) are a subset of hereditary cerebellar ataxias that are autosomal dominantly transmitted. They are progressive neurodegenerative diseases that share the clinical features of ataxia, which arise from the progressive degeneration of the cerebellum but can also affect other connected regions, including the brain stem. They are a highly heterogenous group of disorders with a complex genotype–phenotype spectrum; many SCAs are caused by CAG nucleotide repeat expansions that encode polyglutamine, and therefore, involve the toxic polyglutamine protein (polyQ).
The spinocerebellar ataxias (SCAs) are a large complex group of inherited neurodegenerative disorders characterized by progressive cerebellar ataxia, ocular motor abnormalities, and a range of other variable neurologic features, including retinopathy, optic atrophy, peripheral neuropathy, extrapyramidal symptoms, and cognitive dysfunction.
Symptoms
- Gait ataxia and incoordination
- Nystagmus/visual problems
- Dysarthria
- Extrapyramidal signs
- Ophthalmoplegia
- Cognitive impairment in specific SCAs
A phenotype-first approach remains pertinent in molecular diagnosis of rare genetic disorders. Clinicians should also consider genetic testing for primary episodic ataxias (EA). Advances in next-generation sequencing (NGS) have facilitated further insights into the molecular causes of SCA. Exome sequencing identifies less classical phenotype–genotype correlations and detects new mutations in known cerebellar genes.
Treatment
Advancements in the understanding of pathophysiologic mechanisms facilitate the potential to find new therapeutic targets. Riluzole, a drug licensed for the treatment of ALS, was reconsidered for the treatment of patients with ataxia owing to its ability to inhibit presynaptic glutamate release and activate calcium-activated potassium channels.The anticonvulsant valproic acid has been proposed as a pharmacological treatment in SCA3/MJD for its neuroprotective properties as a pan-histone deacetylase inhibitor. Lithium carbonate was evaluated in 62 ambulatory patients with SCA3/MJD for 48 weeks, but no difference was seen in mean scores of the neurological scale for ataxia. Varenicline is a partial agonist of the ?4?2 neuronal nicotinic acetylcholine receptor that is used to aid the cessation of smoking. Varenicline was anecdotally reported to have beneficial effects in patients with ataxia that were taking it as part of a smoking cessation programme. General supportive management options include physiotherapy, occupational therapy and speech therapy. Physiotherapy focused on improving gait, balance, coordination, posture and muscle strength is often recommended.
Spinocerebellar Ataxias Emerging Drugs Chapters
This segment of the Spinocerebellar Ataxias report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Spinocerebellar Ataxias Emerging Drugs
- KPS-0373: Kissei Pharmaceutical
Further product details are provided in the report……..
Spinocerebellar Ataxias: Therapeutic Assessment
This segment of the report provides insights about the different Spinocerebellar Ataxias drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Spinocerebellar Ataxias
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Spinocerebellar Ataxias: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spinocerebellar Ataxias therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spinocerebellar Ataxias drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spinocerebellar Ataxias R&D. The therapies under development are focused on novel approaches to treat/improve Spinocerebellar Ataxias
- Spinocerebellar Ataxias Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Spinocerebellar Ataxias drugs?
- How many Spinocerebellar Ataxias drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spinocerebellar Ataxias?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spinocerebellar Ataxias therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spinocerebellar Ataxias and their status?
- What are the key designations that have been granted to the emerging drugs?
- Kissei Pharmaceutical
- KPS-0373
Introduction
Executive Summary
Spinocerebellar Ataxias: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Spinocerebellar Ataxias – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Spinocerebellar Ataxias companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Spinocerebellar Ataxias Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
KPS-0373: Kissei Pharmaceutical
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Metopimazine: Neurogastrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Renzapride: Atlantic Healthcare
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
RQ 00201894: RaQualia Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Spinocerebellar Ataxias Key Companies
Spinocerebellar Ataxias Key Products
Spinocerebellar Ataxias - Unmet Needs
Spinocerebellar Ataxias - Market Drivers and Barriers
Spinocerebellar Ataxias - Future Perspectives and Conclusion
Spinocerebellar Ataxias Analyst Views
Spinocerebellar Ataxias Key Companies
Appendix
Executive Summary
Spinocerebellar Ataxias: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Spinocerebellar Ataxias – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Spinocerebellar Ataxias companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Spinocerebellar Ataxias Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
KPS-0373: Kissei Pharmaceutical
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Metopimazine: Neurogastrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Renzapride: Atlantic Healthcare
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
RQ 00201894: RaQualia Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Spinocerebellar Ataxias Key Companies
Spinocerebellar Ataxias Key Products
Spinocerebellar Ataxias - Unmet Needs
Spinocerebellar Ataxias - Market Drivers and Barriers
Spinocerebellar Ataxias - Future Perspectives and Conclusion
Spinocerebellar Ataxias Analyst Views
Spinocerebellar Ataxias Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Gastroparesis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Gastroparesis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Gastroparesis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Gastroparesis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products